Clinical evaluation of therapeutic efficacy of Teriparatide in osteoporotic patients with vertebral degeneration.

Abstract

Osteoporosis is a common age-associated bone disease characterized by the decreased bone density and compromised bone strength. Osteoporotic patients are always at a risk of severe fractures and they experience chronic lumbar pain, highlighting the need for an effective treatment while having lowest side effects. This clinical evaluation of three years from 2018 to 2021 at a single clinic in western Tehran, Iran was aimed to evaluate the therapeutic effects of a biosimilar recombinant teriparatide traded as 'Cinnopar®' to alleviate the back pain and manage thoracolumbar osteoporosis. In this study, a total of 180 osteoporotic patients diagnosed with lower back pain, were enrolled and later on 14 patients were excluded from the study due to lack of cooperation or follow-up. Patients were randomly assigned into two groups, one those who are willingly will be receiving CinnoPar® and second group who will be receiving bisphosphonates at an optimal monthly dose. Data was collected through reviews of medical records and comprehensive regular follow-up was performed via phone interviews to evaluate bone density and pain levels during specific intervals of time. Oswestry Disability Index (ODI) was developed and Short Form Health Survey (SF-36) was performed to analyses the results from two under treatment groups. Significant improvement in pain and functional ability was observed in the patients who received CinnoPar® after two years as compared to the bisphosphonate group (P < 0.05). It was also reported that patients who received CinnoPar® showed improvements in social functioning and pain reduction over the same period of time (P < 0.05). CinnoPar® showed promising results and fall under a minimally invasive treatment category for reducing the lower back pain and managing osteoporosis in lumbar and thoracic vertebrae while having few side effects.